2022 Fiscal Year Final Research Report
Innovation of a novel DN medication by targeting ChREBP
| Project/Area Number |
20H04099
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 59040:Nutrition science and health science-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岩渕 好治 東北大学, 薬学研究科, 教授 (20211766)
横山 敦 東北大学, 医学系研究科, 准教授 (20572332)
岡本 好司 東北大学, 大学病院, 講師 (80572247)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 糖尿病性腎症 / ChREBP / CRISPR-Cas9システム / ChIPアッセイ / 免疫沈降法 |
|---|
| Outline of Final Research Achievements |
We have identified a novel ChREBP inhibitor D-532 which can ameliorate the progression of diabetic nephropathy (DN) in DN model mice. I the present study, we have demonstrated the involvement of ChREBP in the progression of DN by generating ChREBP KO mice by CRISPR-Cas9 system. We have also demonstrated the direct interaction of D-532 and ChREBP. Additionally, D-532 was shown to inhibit the ChREBP binding to its target gene ny ChIP assay. Therefore, D-532 may be a novel therapeutic against DM.
|
| Free Research Field |
内分泌・代謝学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究課題によりChREBPがDNの増悪因子であること、ならびにその阻害薬であるD-532が直接ChREBPを抑制することが明らかとなった。D-532はDNの新規治療薬たり得ると考えられることから、そのDNへの臨床応用・実用化はDN患者さんにとって大きな福音となることが期待される。
|
